Prelude Capital Management, LLC Recursion Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$7.35 - $10.05 $116,085 - $158,729
15,794 New
15,794 $118,000
Q4 2023

Feb 14, 2024
SELL
$5.09 - $10.79 $118,220 - $250,608
-23,226 Reduced 54.07%
19,733 $194,000
Q3 2023

Nov 14, 2023
BUY
$6.59 - $15.86 $43,316 - $104,247
6,573 Added 18.06%
42,959 $328,000
Q2 2023

Aug 14, 2023
BUY
$4.56 - $9.94 $165,920 - $361,676
36,386 New
36,386 $271,000
Q2 2022

Aug 15, 2022
BUY
$5.04 - $9.26 $91,944 - $168,930
18,243 New
18,243 $148,000

Others Institutions Holding RXRX

# of Institutions
289
Shares Held
242M
Call Options Held
1.35M
Put Options Held
2.32M
View Full List

About RECURSION PHARMACEUTICALS, INC.

RXRX Quotes by TradingView
  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.18B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email